CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

Data ReadoutpositiveVyalevPositive
AI Analysis

Summary

AbbVie presented real-world data from a 12-month study supporting the safety and efficacy of Vyalev in Parkinson's disease patients at EAN 2026.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Real-world data study demonstrated safety and efficacy in Parkinson's disease patients over 12 months

Importance:5/10
Sentiment:
0.70
real-world dataParkinson's diseasesafetyefficacyEAN 2026
Related Companies
$ABBV

Read the original article

Published by Clinical Trials Arena on July 1, 2026 12:50 PM

Read Original